Support for coronavirus vaccine and COVID-19 therapy production

New vaccines and other therapeutics that have the promise to treat or immunize from the coronavirus disease (COVID-19) will move from research and development to clinical trials, then full-scale manufacturing with speed, quality and confidence.

At the same time, there is surging demand for existing therapies, like monoclonal antibody (mAbs) typically used to treat autoimmune conditions like rheumatoid arthritis, which are now being fast-tracked back through clinical trials to determine their effectiveness in treating symptoms of COVID-19 to save lives more immediately. As a trusted partner to leading biotech and pharmaceutical companies in the world, Avantor® is ready with the resources and collaborative support our customers need to solve their toughest mAbs and vaccine production challenges.

We bring our regulatory, quality and technical expertise to virtually every step of production process to drive the efficiency that enables treatments to get to the patients and communities that need them, quickly and safely.

Resources to move production forward

Our broad portfolio of products engineered to satisfy the highest quality standards and regulatory requirements for production of mAbs and vaccines:

cGMP manufactured chemicals and reagents to improve the overall quality of the therapy and allow for more efficient scale-up, such as J.T.Baker® cGMP grade IPTG and custom packaged, pre-weighed raw materials and excipients available through our J.T.Baker® Direct Dispense packaging platform.

Process chromatography resins engineered to improve downstream production efficiency, such as the new J.T.Baker® BAKERBOND® PROchievA™ recombinant protein A resin as well as other BAKERBOND chromatography resin offerings addressing ion exchange, mixed-mode hydrophobic interaction, normal phase and silica reversed phase.

Single-use products for more efficient aseptic sampling and fluid transfer, including the Avantor OmniTop Sample Tubes® Adjustable Volume Sampling System (AVSS) for precision closed-system sampling of high value mAbs.

Avantor Seradigm serum, produced using unique collection and manufacturing techniques that preserve more of the naturally occurring growth factors that cells require to thrive.

Products for vaccine and therapy production

Get details on our bioprocessing solutions available through VWR, part of Avantor.

To find a channel partner in your region, please click here.

Vaccine manufacturing: COVID-19 and beyond

In this interview, Nandu Deorkar, Vice President of R&D, Biopharma Production at Avantor, shares lessons we can learn from the industry’s historic ramp-up from research to manufacturing.

Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world.